Physician profile
Anas Kayal
NPI 1851376917
$6,965.05
in general payments reported to CMS, 2019-2025
26 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.81 · 2021: $756 · 2022: $1,206 · 2023: $2,113 · 2024: $1,860 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918 · Education: $63.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.77 |
| Education | $63.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,236.56 | 2021-2025 | Krystexxa, Tavneos, Uplizna |
| Aurinia Pharma U.S., INC. | $913.86 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $846.74 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $781.99 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $639.27 | 2022-2025 | Farxiga, Lokelma, Saphnelo |
| Mallinckrodt Hospital Products INC. | $388.34 | 2022-2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $286.29 | 2021-2023 | Strensiq, Ultomiris |
| Ani Pharmaceuticals, INC. | $209.71 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $181.65 | 2022-2025 | Olumiant, Taltz, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $171.20 | 2021-2022 | |
| Ucb, INC. | $150.13 | 2022-2025 | Cimzia, Bimzelx |
| Calliditas Therapeutics US INC. | $144.64 | 2023-2024 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.62 | 2023-2025 | Jardiance |
| Janssen Biotech, INC. | $131.68 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $124.95 | 2024 | Xphozah 30 Mg |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $111.67 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $106.67 | 2019-2023 | Jynarque |
| Novartis Pharmaceuticals Corporation | $99.47 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.30 | 2022-2024 | Opsumit, Uptravi |
| Opko Pharmaceuticals, LLC | $72.55 | 2022-2023 | Rayaldee |
| Sandoz INC. | $24.19 | 2025 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $23.95 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $22.87 | 2024 | |
| Abbvie INC. | $22.33 | 2023 | |
| Novo Nordisk INC | $18.94 | 2023 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $14.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Kayal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.